Implementing Effective Early Phase Trial Strategies in Asia to Reduce Approval Timelines, Risks and Costs from First-In-Human through Proof of Concept

Asia’s ONLY Early Phase Clinical Trials Event!

Development trend for Early Phase Clinical Trials in Asia
In March 2012, the number of clinical trials registered in Asia reached almost 19,922. Also, we have seen a significant increase in the number of early phase clinical trials conducted in Asia with more and more multinational pharmaceutical and biopharmaceutical companies planning early phase clinical trials including First-in-Human trials in the next 2 years.

Expert Speaker Faculty

  • danny-soon Danny Soon
    Managing Director & Principal Investigator
    Lilly-NUS Centre for Clinical Pharmacology, Singapore

    Zaiqi-Wang Zaiqi Wang
    Director of Clinical Research
    Singapore MSD Translational Research Centre

    Devan-Parmar1 Deven Parmar
    Vice President - Global Clinical Research
    Wockhardt
  • Hanlim-Moon Hanlim Moon
    CEO
    CUREnCARE Research

    Rupesh-Patki Rupesh Patki
    Regional Area Manager, Asia Global Monitoring Operations
    Allergan Singapore

    nospeaker1 Joalin Lim
    Director, Clinical Affairs
    Covidien
  • Melvin-Toh Melvin Toh
    Vice President of Clinical &
    Regulatory Affairs
    CK Life Sciences International

    Joanne Chio Joanne Chio
    Head of Clinical Trials, Haematology –Oncology Research Group (HORG)
    National University Hospital, Singapore

    Ling-Su Ling Su
    Senior Vice President & Head of Development Greater China
    Novartis
  • Charlie-Xu Charlie Xu
    Vice President, Clinical Services
    Frontage Lab China

    nospeaker1 Mark McHale
    Chief Scientific Officer
    ASLAN

    nospeaker1 Akhilesh Sharma
    VP & Global Head of Clinical Management & Global Pharmacovigilance
    Dr Reddy's Laboratories
  • nospeaker1 Christine Dela Cruz
    Director, Global Clinical Research – Oncology
    Bristol-Myers Squibb

    nospeaker1 Aung Myo
    Head of Clinical Development, Cancer Immunotherapeutics, Asia-Pacific(APJEM)
    GlaxoSmithKline Biologicals

In order to help clinical experts overcome regulatory, risk and cost challenges for early phase clinical development in Asia, the 2nd Annual Early Phase Clinical Trials Asia 2012 is returning this August as a high-level platform to gather Heads of Clinical Development/Research, Medical Directors and Heads of clinical operation related departments from pharmaceutical and biopharmaceutical companies and CROs from Mainland China, India, Taiwan, Korea, Hong Kong and other Southeast Asian countries.

>> Download the brochure to find out more

>> Find out who’s attending Early Phase Clinical Trials Asia

They will share their experience area including:

  • Early phase clinical development strategies
  • Clinical modelling and simulation
  • Translational strategies
  • Biomarkers and bio analyses
  • Imaging and data management

If you provide equipment products and services into the early phase clinical trial industry, then the 2nd Annual Early Phase Clinical Trials Asia will be your perfect stage to reach out to your potential clients!

>> Find out more on sponsoring and exhibiting

>> Register now

Attend Early Phase Clinical Trials Asia 2012 and:

  • Gain direct access to an elite audience of senior level decision makers from early phase clinical development market active participants
  • Brand your company as a key provider of services and solutions for the early phase clinical development through over 6 hours’ networking opportunities
  • Meet a wide variety of key decision makers and walk away with business development opportunities that lead to new businesses now and well into the future
  • Associate yourself with Asia Pacific’s ONLY early phase clinical trial summit to deliver pre & post event exposure and continuity

>> Register Now

>> Find out more on sponsoring and exhibiting

Key conference highlights for Early Stage Clinical Trials Asia 2012 include:

  • Effective approaches to overcome regulatory challenges for early phase trial approval in China, India and Korea
  • Translational strategy: Aligning preclinical models with optimised clinical strategy
  • Designing a streamlined safety early phase study to mitigate risks and costs
  • Outsourcing strategies and partnership selection and maintenance with CROs
  • Utilising effective modelling and simulation tools – Examining how this has been successfully used

>> View the agenda now

>> Register now

Media Partners
_mediapartners

[ Register Now ]